Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Myelofibrosis | Current Treatment: Physician Insights | US | 2020

Login to access report north_east
Contact sales account_box

Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Ruxolitinib (Jakafi, approved in November 2011) and fedratinib (Inrebic, approved in August 2019) are the only two FDA-approved drugs for MF in the United States. Although Jakafi offers a therapeutic option, it is associated with high discontinuation rates and loss of response, and it does not address all MF symptoms. Therefore, significant market opportunity remains for safe and tolerable treatments that can manage the full spectrum of symptoms, as well as for treatment options for patients with baseline thrombocytopenia and anemia. This report explores the current prescribing practices for MF, the various factors driving treatment decisions, and the changes in prescribing that are expected to occur in the coming year.

QUESTIONS ANSWERED

  • Which symptoms do surveyed hematologists cite as the most common among their MF patients? How do hematologists approach the management of MF patients? What factors drive physicians’ prescribing?
  •  What percentage of MF patients progress from one line of therapy to another based on severity? What is the treatment duration before progressing?
  •  Which drugs are the patient-share leaders in MF? How is Jakafi positioned in surveyed physicians’ treatment algorithms? What was the initial impact of Inrebic in the management of MF?
  • What are prescribers’ estimates regarding patients’ compliance with current therapies?
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east